BDAZ

Thanks for sharing that information.

I am trying my best to digest these technical reports but usually get lost along the way - science and medicene are not my forte. I can grasp the MACE endpoints of the BetonMace trial, and the claim that ZEN-3694 inhibits resistance to therapies. Both ZEN-3694 and RVX-222 Synergize with other treatments to achieve their outcomes. Are Zen-3694 and RVX-222 additives that must always be used with other therapies? Must they be specifically designed for each combination? Can BET Bromodomain Inhibition be targeted with any therapy? Can it be successful independently as in reverse cholesteral transport? I'm just trying to take it all in.

Chicagoest